Sidoti Csr Expects Weaker Earnings for USANA Health Sciences

USANA Health Sciences, Inc. (NYSE:USNA) – Analysts at Sidoti Csr cut their FY2024 EPS estimates for USANA Health Sciences in a research report issued on Wednesday, October 23rd. Sidoti Csr analyst A. Lebiedzinski now forecasts that the company will earn $2.45 per share for the year, down from their previous forecast of $2.48. The consensus estimate for USANA Health Sciences’ current full-year earnings is $2.50 per share. Sidoti Csr also issued estimates for USANA Health Sciences’ Q4 2024 earnings at $0.49 EPS, Q1 2025 earnings at $0.73 EPS, Q2 2025 earnings at $0.61 EPS, Q3 2025 earnings at $0.64 EPS, Q4 2025 earnings at $0.75 EPS, FY2025 earnings at $2.74 EPS, Q1 2026 earnings at $0.82 EPS, Q2 2026 earnings at $0.74 EPS, Q3 2026 earnings at $0.77 EPS and FY2026 earnings at $3.20 EPS.

USNA has been the subject of several other reports. StockNews.com lowered shares of USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 24th. DA Davidson dropped their price objective on shares of USANA Health Sciences from $38.00 to $35.00 and set a “neutral” rating for the company in a report on Wednesday.

USANA Health Sciences Price Performance

Shares of NYSE:USNA opened at $36.81 on Thursday. The company has a market cap of $701.27 million, a price-to-earnings ratio of 11.47, a PEG ratio of 1.15 and a beta of 0.89. USANA Health Sciences has a one year low of $34.15 and a one year high of $54.81. The firm has a fifty day moving average price of $37.90 and a two-hundred day moving average price of $42.44.

USANA Health Sciences (NYSE:USNA) last issued its earnings results on Tuesday, October 22nd. The company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.49 by $0.07. USANA Health Sciences had a return on equity of 10.80% and a net margin of 6.30%. The business had revenue of $200.22 million during the quarter, compared to the consensus estimate of $208.45 million. During the same quarter last year, the company earned $0.59 EPS.

Insider Buying and Selling at USANA Health Sciences

In related news, Director Gilbert A. Fuller sold 674 shares of the firm’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $39.69, for a total value of $26,751.06. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, Director John Turman Fleming sold 1,000 shares of USANA Health Sciences stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $44.43, for a total transaction of $44,430.00. Following the sale, the director now owns 2,503 shares of the company’s stock, valued at approximately $111,208.29. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Gilbert A. Fuller sold 674 shares of the stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $39.69, for a total transaction of $26,751.06. The disclosure for this sale can be found here. Insiders sold 7,940 shares of company stock valued at $311,670 in the last quarter. Company insiders own 0.33% of the company’s stock.

Hedge Funds Weigh In On USANA Health Sciences

A number of institutional investors have recently added to or reduced their stakes in the company. Pzena Investment Management LLC grew its stake in shares of USANA Health Sciences by 24.4% in the second quarter. Pzena Investment Management LLC now owns 976,633 shares of the company’s stock worth $44,183,000 after acquiring an additional 191,289 shares during the last quarter. Dimensional Fund Advisors LP grew its position in USANA Health Sciences by 0.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 683,158 shares of the company’s stock valued at $30,907,000 after purchasing an additional 3,889 shares during the last quarter. Pacer Advisors Inc. raised its holdings in USANA Health Sciences by 14.3% in the second quarter. Pacer Advisors Inc. now owns 467,352 shares of the company’s stock worth $21,143,000 after buying an additional 58,597 shares during the last quarter. American Century Companies Inc. lifted its stake in shares of USANA Health Sciences by 12.3% in the second quarter. American Century Companies Inc. now owns 159,782 shares of the company’s stock worth $7,229,000 after buying an additional 17,460 shares in the last quarter. Finally, Assenagon Asset Management S.A. grew its holdings in shares of USANA Health Sciences by 13.5% during the third quarter. Assenagon Asset Management S.A. now owns 124,008 shares of the company’s stock valued at $4,702,000 after buying an additional 14,756 shares during the last quarter. Institutional investors own 54.25% of the company’s stock.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.